Revised response criteria for malignant lymphoma
| Autor: | Cheson, Bd, Pfistner, B, Juweid, Me, Gascoyne, Rd, Specht, L, Horning, Sj, Coiffier, B, Fisher, Ri, Hagenbeek, A, Zucca, E, Rosen, St, Stroobants, S, Lister, Ta, Hoppe, Rt, Dreyling, M, Tobinai, K, Vose, Jm, Connors, Jm, Federico, Massimo, Diehl, V, THE INTERNATIONAL HARMONIZATION PROJECT ON LYMPHOMA |
|---|---|
| Přispěvatelé: | CCA -Cancer Center Amsterdam, Clinical Haematology |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Cancer Research
medicine.medical_specialty Time Factors Endpoint Determination response criteria Aggressive Non-Hodgkin Lymphoma International Prognostic Index Fluorodeoxyglucose F18 Terminology as Topic Image Interpretation Computer-Assisted medicine Refractory Hodgkin Lymphoma Indolent Non-Hodgkin Lymphoma Humans Medical physics Brentuximab vedotin Clinical Trials as Topic clinical trials business.industry Lymphoma Non-Hodgkin medicine.disease Flow Cytometry Hodgkin Disease Immunohistochemistry Survival Analysis Polatuzumab vedotin Clinical trial malignant lymphoma Treatment Outcome Oncology Positron-Emission Tomography Immunology Primary mediastinal B-cell lymphoma Radiopharmaceuticals business Tomography X-Ray Computed medicine.drug |
| Zdroj: | Journal of clinical oncology, 25(5), 579-586. American Society of Clinical Oncology |
| ISSN: | 0732-183X |
| Popis: | Purpose Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Methods The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. Results New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. Conclusion We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|